Literature DB >> 24598959

Development of cardioplegic solution without potassium: experimental study in rat.

Karla Reichert, Helison Rafael Pereira do Carmo, Fany Lima, Anali Galluce Torina, Karlos Alexandre de Souza Vilarinho, Pedro Paulo Martins de Oliveira, Lindemberg Mota Silveira Filho, Elaine Soraya Barbosa de Oliveira Severino, Orlando Petrucci.   

Abstract

INTRODUCTION: Myocardial preservation during open heart surgeries and harvesting for transplant are of great importance. The heart at the end of procedure has to resume its functions as soon as possible. All cardioplegic solutions are based on potassium for induction of cardioplegic arrest.
OBJECTIVE: To assess a cardioplegic solution with no potassium addition to the formula with two other commercially available cardioplegic solutions. The comparative assessment was based on cytotoxicity, adenosine triphosphate myocardial preservation, and caspase 3 activity. The tested solution (LIRM) uses low doses of sodium channel blocker (lidocaine), potassium channel opener (cromakalin), and actin/myosin cross bridge inhibitor (2,3-butanedione monoxime).
METHODS: Wistar rats underwent thoracotomy under mechanical ventilation and three different solutions were used for "in situ" perfusion for cardioplegic arrest induction: Custodiol (HTK), Braile (G/A), and LIRM solutions. After cardiac arrest, the hearts were excised and kept in cold storage for 4 hours. After this period, the hearts were assessed with optical light microscopy, myocardial ATP content and caspase 3 activity. All three solutions were evaluated for direct cytotoxicity with L929 and WEHI-164 cells.
RESULTS: The ATP content was higher in the Custodiol group compared to two other solutions (P<0.05). The caspase activity was lower in the HTK group compared to LIRM and G/A solutions (P<0.01). The LIRM solution showed lower caspase activity compared to Braile solution (P<0.01). All solutions showed no cytotoxicity effect after 24 hours of cells exposure to cardioplegic solutions.
CONCLUSION: Cardioplegia solutions without potassium are promised and aminoacid addition might be an interesting strategy. More evaluation is necessary for an optimal cardioplegic solution development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24598959      PMCID: PMC4389432          DOI: 10.5935/1678-9741.20130085

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  24 in total

1.  Reconstruction of the electrical activity of cardiac Purkinje fibres.

Authors:  R E McAllister; D Noble; R W Tsien
Journal:  J Physiol       Date:  1975-09       Impact factor: 5.182

2.  Elective cardiac arrest.

Authors:  D G MELROSE; B DREYER; H H BENTALL; J B BAKER
Journal:  Lancet       Date:  1955-07-02       Impact factor: 79.321

3.  Custodiol versus blood cardioplegia in complex cardiac operations: an Australian experience.

Authors:  Fabiano F Viana; William Y Shi; Philip A Hayward; Marco E Larobina; Frank Liskaser; George Matalanis
Journal:  Eur J Cardiothorac Surg       Date:  2012-06-04       Impact factor: 4.191

Review 4.  Targeting for cardioplegia: arresting agents and their safety.

Authors:  Hazem B Fallouh; Jonathan C Kentish; David J Chambers
Journal:  Curr Opin Pharmacol       Date:  2009-04       Impact factor: 5.547

Review 5.  Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion.

Authors:  David J Chambers; Hazem B Fallouh
Journal:  Pharmacol Ther       Date:  2010-04-14       Impact factor: 12.310

6.  Eight hours of cold static storage with adenosine and lidocaine (Adenocaine) heart preservation solutions: toward therapeutic suspended animation.

Authors:  Donna M Rudd; Geoffrey P Dobson
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-13       Impact factor: 5.209

7.  How does hypothermia protect cardiomyocytes during cardioplegic ischemia?

Authors:  Cornelia Drescher; Antje Diestel; Sonja Wollersheim; Felix Berger; Katharina R L Schmitt
Journal:  Eur J Cardiothorac Surg       Date:  2011-01-15       Impact factor: 4.191

8.  Forty-hour preservation of the rabbit heart: optimal osmolarity, [Mg2+], and pH of a modified UW solution.

Authors:  J C Stringham; K L Paulsen; J H Southard; R M Mentzer; F O Belzer
Journal:  Ann Thorac Surg       Date:  1994-07       Impact factor: 4.330

9.  Trimetazidine as cardioplegia addictive without pre-treatment does not improve myocardial protection: study in a swine working heart model.

Authors:  Lindemberg da Mota Silveira Filho; Orlando Petrucci; Marcio Roberto de Carmo; Pedro Paulo Martins de Oliveira; Karlos Alexandre Sousa Vilarinho; Reinaldo Wilson Vieira; Domingo Marcolino Braile
Journal:  Rev Bras Cir Cardiovasc       Date:  2008 Apr-Jun

10.  Endothelial dysfunction after long-term cold storage in HTK organ preservation solutions: effects of iron chelators and N-alpha-acetyl-L-histidine.

Authors:  Tamás Radovits; Li-ni Lin; Julia Zotkina; Achim Koch; Ursula Rauen; Gernot Köhler; Matthias Karck; Gábor Szabó
Journal:  J Heart Lung Transplant       Date:  2008-02       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.